Profile data is unavailable for this security.
Mergers & acquisitions
Acquired company | LLY:NYQ since announced | Transaction value |
---|---|---|
Mablink Bioscience SAS | 26.16% | -- |
POINT Biopharma Global Inc | 44.52% | 1.38bn |
Versanis Bio Inc | 78.96% | 1.93bn |
Emergence Therapeutics AG | 69.60% | 8.33m |
Sigilon Therapeutics Inc | 69.60% | 316.64m |
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
Holder | Shares | % Held |
---|---|---|
Caixa DTVM SAas of 31 Oct 2023 | 450.81k | 0.00% |
Western Asset Management Company DTVM Ltda.as of 31 Oct 2023 | 215.76k | 0.00% |
Bram Bradesco Asset Management S/A DTVMas of 30 Nov 2023 | 59.53k | 0.00% |
Safra Asset Management Ltda.as of 30 Nov 2023 | 47.00k | 0.00% |
BB Gest�o de Recursos DTVM SAas of 31 Oct 2023 | 9.90k | 0.00% |
XP Allocation Asset Management Ltda.as of 31 Oct 2023 | 1.41k | 0.00% |
More ▼
Data from 30 Nov 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.